Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/jcm11102840
Keywords
cytoreductive surgery (CRS); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal surface malignancies (PSM); peritoneal carcinomatosis; colorectal cancer; appendiceal cancer
Categories
Funding
- NIH Training Grant [T32CA160003]
Ask authors/readers for more resources
Peritoneal carcinomatosis is a poor prognostic factor for all malignancies and systemic therapies have limited efficacy. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are surgical interventions that have improved outcomes, but long-term survival remains rare and recurrence is common. Therefore, the development of novel therapeutics and techniques is necessary to improve outcomes.
Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available